Building a NBE pre-formulation screening funnel to accelerate biologics drug development in China

---

Jinming Gu

Shanghai Hengrui Pharmaceutical Co., China

: J Pharm Drug Deliv Res

Abstract

---

Antibody-based therapeutics has become the driving force of the pharmaceutical industry. With 61 different antibody-based drugs on the market by 2015, antibody-based therapeutics has brought 90.6 billion USD to the industry in 2015 and keeps growing at a phenomenon speed. However, the biopharmaceutical industry is also facing issues such as patent expiration, new target identification, drug resistance etc. How to bring a biologics drug to the patients at a fast pace is one of the top priorities in the field? One of the major bottlenecks in biologics drug discovery and development is drug pre-formulation. This presentation will discuss how we build a world-class high throughput new biologics entity (NBE) pre-formulation screening funnel to accelerate biologics drug development in China.

Biography

---

Email: gujm@shhrp.com